Thermo has shipped its 100th linear ion trap mass spectrometer, to Incaps in Indiana, USA, just a year after the instrument was launched
Thermo Electron announces the 100th customer shipment of the Finnigan LTQ high performance linear ion trap mass spectrometer. The system was one of five Finnigan LTQs purchased by the Indiana Centers for Applied Protein Sciences (Incaps).
Incaps is a recently established venture between Eli Lilly and leading academic, industry and US government organisations. "Incaps's mission is to provide both academic and industry researchers of the Indiana community and beyond with the most advanced commercially available and prototype proteomics instrumentation to customers requiring high quality proteomic analysis," says James Ludwig, CEO of Incaps.
Dr Ludwig adds: "Incaps is very pleased to receive the 100th Finnigan LTQ instrument shipped by Thermo Electron.
"Its objectives are further advanced by the addition of this instrument.
"We expect the LTQ to become a workhorse for our biomarker discovery effort for many years to come.
"Thermo Electron has been a very committed and collaborative partner, and we look forward to continuing with validating and implementing their very best technologies".
Thermo Electron says it set new standards of performance for proteomics research and metabolic studies with the introduction of the Finnigan LTQ at ASMS 2003.
Incorporating novel and patented technologies, the Finnigan LTQ delivers exceptional protein sequence coverage with sub-femtomole full-scan LC/MS/MS sensitivity at breakthrough speed.
This instrument is, says Thermo, recognised by leading research and government institutions, and by major pharmaceutical and biotech companies worldwide for delivering unprecedented performance in the identification and the mapping of post-translational modifications.
It is also recognised for accelerating early discovery phase investigations, and in the analysis, detection, and quantification of the most minor components in complex biological matrices.
Researchers have a powerful tool for characterising disease states and mechanisms of action with the Finnigan LTQ FT, as well as for developing new diagnostic and therapeutic strategies.
The 100th Finnigan LTQ customer shipment marks a key milestone in the adoption of new linear trap technology in the marketplace, and demonstrates Thermo's continued leadership in ion trap mass spectrometry.
Thermo continues to provide the scientific community with breakthrough technology for the advancement of science.
